Tiny Float Breakout Idea (HILS) Is A Nasdaq Biotech Rocking A Red Hot Chart

Warning: Invalid argument supplied for foreach() in /home/customer/www/vj.media/public_html/wp-content/plugins/vjmedia-polygon-api/vjmedia-polygon-api.php on line 100

2/10/23 *UPDATE*

Greetings Readers,

Still tracking my last alert, Hillstream BioPharma, Inc. (HILS)?

If not, you’re missing out on something special.

Brought to your attention on the morning of January 30th, it opened that session at $.596.

As of pre-market today, it was trading at over $2.00!

That’s an incredible surge of approximately 235+% in less than 2 weeks.

Part of today’s big move comes from this huge company announcement: In a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis Inducer

HILS is also trading above 3 of the most important lines of potential support including its 50-Day Simple Moving Average (SMA), its 200-Day SMA, and its 13-Day Exponential Moving Average (EMA).

Don’t forget. This is a low float idea. With fewer than 4Mn shares available according to Yahoo Finance, HILS is a target for significant volatility at any given moment.

If more updates pop up, I’ll have them out to you quickly.

Sincerely, 

Virtus Junxit

1/30/23

Greetings Readers,

Biotech companies are quickly becoming an essential part of the modern economy.

Developing cutting-edge products and treatments, they are revolutionizing how we view and approach health and healing.

In fact, there are several reasons why one might want to closely watch biotech companies:

• Biotechnology companies often have a large potential for growth, as they are often working on developing new and innovative products and treatments.

• They are often at the forefront of advances in medicine and technology, which can lead to significant breakthroughs.

• Biotech companies are often focused on developing treatments for serious or life-threatening illnesses, which can lead to strong demand for their products and services.

• Biotech companies can often have a high level of volatility, which may lead to significant valuation swings.

We’ve been tracking one such biotech company closely and want to bring them to your attention right now.

For Monday, January 30th, get Hillstream BioPharma, Inc. (HILS) on your radar.

And based on its low float, a red hot chart to start 2023, it trading above multiple likes of potential support, and a pipeline signaling the potential for a very bright future, this Nasdaq breakout idea requires immediate attention. 

Full Company Overview: Hillstream BioPharma, Inc. (HILS)

Hillstream Biopharma is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for drug resistant and devastating cancers.

Hillstream’s most advanced candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors.

Hillstream uses Quatramer™, our proprietary tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor microenvironment with an extended duration of action and minimal off-target toxicity.

In addition, Trident Artificial Intelligence (TAI), Hillstream’s artificial intelligence precision medicine platform, is used to identify biomarkers in our clinical programs to target a specific patient segment most likely to benefit.

Hillstream BioPharma Pipeline 

—–

Quatramer Platform

Quatramer is tumor-targeted platform with capacity to deliver drug and biologic combinations

Quatramer is a tumor targeting platform which allows us to leverage and exploit key tumor targets and novel emerging pathways such as IMCD to facilitate the delivery of potent drugs directly to the TME, while sparing healthy tissue. By efficiently extending the circulation half-life, as well as targeting delivery to the tumor site, Quatramer traps drugs into the TME. This emerging orthogonal anti-cancer approach utilizes a fundamental recognized mechanism of iron mediated tumor growth and metabolism. We are building a portfolio of long-acting, potent anti-cancer drug candidates using our Quatramer platform.

Quatramer based compounds with therapeutic cargoes from our product pipeline include DNA-based contents which hijack the tumor’s genetic code and kill the tumor from within by generating an array of cancer killing cytokines, such as TNF-alpha and potentially others. The platform’s tunability stems from the fact that the system can be modified and adjusted to deliver single or multiple ratios of payloads in order to optimize synergistic mechanisms of action in lower doses in order to eradicate rare cancers and treatment resistant tumors with minimal or no treatment options.

TridentAI Platform

Trident is a Deep Learning Engine that identifies synthetic lethal sensitivities associated with degree of cell plasticity

Trident, as the name suggests, takes a multi-pronged approach to address each of the leading causes of tumor plasticity as the disease progresses namely Epithelial-to-mesenchymal transition, Dedifferentiation/Transdifferentiation, and Transient drug-induced tolerance and sensitivity. The platform builds on a deep foundation of diverse multi-modal and multi-omic private and public datasets which include not only genomic and transcriptomic data from patient derived blood or biopsy samples and sublines, and pan-cancer epigenetic and transcriptional drug response data from The Cancer Genome Atlas (TCGA), Cancer Cell Line Encyclopedia (CCLE) and Genomics of Drug Sensitivity in Cancer (GDSC), but also human cancer proteome datasets from emerging global efforts that include Human Cancer Proteome Project (HUPO; Cancer-HPP), The Cancer Proteome Atlas (TCPA) and The National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC). Inclusion of proteomics data is very critical for identifying dynamical re-wiring of intra-tumoral signaling circuitry which is likely to be missed if one looks at the genomic and transcriptomic level alone.

Trident is a Deep Learning Engine that integrates in vitro and in vivo epigenetic, transcriptomic and proteomic data characterizing genomic alterations, methylation states, cellular differentiation, and drug tolerance to identify:

Biomarker fingerprints that deconvolve a heterogeneous tumor biopsy into a discrete phenotypic state along a gradient of progressive cellular plasticity, Network of dis-regulated functional pathways that underscore a patient’s pathology, and Indication-specific synthetic-lethal sensitivities to drugs

Trident utilizes state-of-the-art convolutional neural networks to classify and select patients based on their tumor-derived multi-comic profiles thus enabling a targeted synthetic-lethal approach to kill persistent tumor cell populations and treat patients in select indications.

Trident maps the phenotypic tumor transition from a high-dimensional landscape onto a quantitative, measurable one-dimensional scale

Trident traces the complex high-dimensional landscape of tumor progression to identify biomarkers that mark milestones in this continuum and enable quantification of degree of plasticity along the trajectory. Trident’s Deep Learning Engine trains a model that can reduce this high-dimensional information into a one-dimensional quantitative and measurable scale which informs what is the degree of plasticity in a biopsy sample or cell line dataset. Trident’s unbiased search in the vast repository of multi-modal datasets enables identification of synthetic lethal sensitivities that correlate linearly but contrast with degree of plasticity. This biomarker-guided, state-specific approach enables to successfully deconvolve signals from a heterogenous tumor biopsy into a discrete phenotypic state along a gradient of progressive and divergent cellular plasticity and complementary synthetic lethal sensitivity.

Trident is designed to de-risk clinical development and deliver on the promise of precision medicine

Trident is designed to deliver on Hillstream Bio’s ultimate goal, which is to identify and treat the right patients that are most likely to benefit from treatment. Using Trident, biomarkers measured in patient blood/biopsy samples will assist in determining the degree of plasticity for a specific patient, which will then directly inform about a patient’s sensitivity to activation/inhibition of the synthetically lethal target and probability of successful treatment. More than just de-risking clinical development, Trident aspires to deliver on the promise of precision medicine by building a platform based on the robust foundation of patient-based biomarker research and deep learning artificial intelligence technologies.

Grab more important company details here.

—–

These 3 Potential Catalysts Could Provide (HILS) With A Near Term Breakout Spark

#1. HILS has a very small float.

According to Yahoo Finance, HILS has a float of approximately 3.89Mn shares.

Why is that important? One word: Volatility.

When a profile has so few shares available for trading, volatility can take hold in a moment’s notice.

It could also explain what happened to HILS on December 9th, 2022.

That morning saw this Nasdaq profile open at $.4201 and run to a high of $1.06 on the day.

HILS intraday surged resulted in it blazing a path of 152% in the blink of an eye.

Like I said, volatile.

—–

#2. A Recent Collaboration Agreement Could Be A True Game-Changing Event For HILS.

Check this recent news out:

Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies™ (HSB-1940) against PD-1, by combining Quatramers™ with OmniAb’s Picobodies™, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets

Collaboration allows Hillstream to enter the rapidly growing Immuno-oncology therapeutics market

By capitalizing on the long half-life of tumor targeting Quatramers™ combined with OmniTaur™-derived Picobodies™, the lead program, HSB-1940, is being developed to target PD-1

Picobodies are the smallest known antibody fragment, comprised of ultra-long CDR H3 sequences of 30-40 amino acids rich with cysteines that create tightly folded structures capable of binding recessed epitopes

BRIDGEWATER, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) — Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream”, the “Company”) today announced the development of proprietary targeted biologics, Knob Quatrabodies™ (HSB-1940) against PD-1. Hillstream signed separate collaboration agreements with a subsidiary of OmniAb, Inc. (Nasdaq: OABI) (“OmniAb”) and with Minotaur Therapeutics, Inc. (“Minotaur”) to advance Picobodies against novel, unreachable and undruggable epitopes in high-value validated targets starting with PD-1.

The technologies of Hillstream and Minotaur will be combined under a previously disclosed license from OmniAb to discover, develop and advance biotherapeutics against high-value validated targets. Picobodies are antibody “knob” domains comprised of cysteine-rich ultralong complementary determining region (CDR) H3 sequences of 30-40 amino acids, which have the potential to access challenging epitopes better than full size antibodies can.

By combining Quatramers with their long half-life coated with a PD-1 Picobody™ to create HSB-1940, Hillstream believes it could more efficiently target novel epitopes with greater binding affinity than approved biologics. Targeting PD-1 is a step toward enabling Hillstream to enter the rapidly growing Immuno-oncology (IO) therapeutics market with additional IO targets after PD-L1.

Dr. Vaughn Smider, Founder and Chief Executive Officer of Minotaur, stated, “We are excited to contribute our expertise to help in combining OmniAb’s OmniTaur-derived ultralong CDR H3 antibody fragments and Hillstream’s tumor-targeting Quatramers to discover and develop novel next-generation targeted cancer therapeutics.”

…

Randy Milby, Chief Executive Officer of Hillstream, stated, “The Picobodies which OmniAb brings to this collaboration combined with our Quatramers to create a novel and disruptive Knob Quatramer platform will be a great addition to our portfolio starting with HSB-1940. We are doubly excited that Dr. Vaughn Smider, a pioneer in the discovery, engineering and understanding of these unique proteins, will be leading Minotaur’s services. The Quatramer is a key Hillstream platform which is now poised to create novel therapeutics using “smart carriers” with multiple approaches for enhancing targeted cancer immunotherapy.”

Read the complete article here.

—–

#3. A Red Hot Start To 2023 Has HILS Trading Above Multiple Lines Of Potential Support.

Take a look at HILS chart:

(Source)

That’s right. Since the very end of December, HILS has made a clean 2X move.

From a low of $.3030 on December 28th to HILS high of $.63 this past week, it has made a strong vertical push of 107%.

But here’s the interesting part…

HILS is now trading above multiple lines of potential support. Those lines include its:

• 20-Day Simple Moving Average (SMA)
• 50-Day SMA
• 5-Day Exponential Moving Average (EMA)
• 13-Day EMA

If potential support continues to grow at those levels, it could put HILS in a potential squeeze scenario as it keeps moving closer and closer to its 200-Day SMA at just over $.80+ at the moment.

And when squeezes happen, anything can happen.

Especially when you factor in HILS low float of fewer than 4Mn shares.

These will be important lines to watch closely moving forward.

—–

You’re officially on the clock. The opening bell is going to be on us before you know it.

Drop what you’re doing to get Hillstream BioPharma, Inc. (HILS) on your radar immediately.

If there are any updates today, I’ll have them out to you quickly.

Sincerely, 

Virtus Junxit